The University of Copenhagen proudly announces Haut.AI as a Tier 3 Sponsor for the upcoming 12th Aging Research & Drug Discovery Meeting (ARDD), scheduled to take place from August 25 to August 29, 2025. This event, the largest of its kind in the biotechnology sector focusing on aging, will be held both on-site at the Ceremonial Hall of the University of Copenhagen and virtually, enabling global participation. ARDD consistently serves as an unparalleled platform for advancing the science and innovation underpinning longevity and age-related therapeutics.
Haut.AI stands at the forefront of integrating cutting-edge artificial intelligence, particularly generative AI technologies, into the domain of skin health and personalized skincare solutions. The company’s foundation is deeply rooted in interdisciplinary scientific expertise, encompassing artificial intelligence, biology, biophysics, and dermatology. This multifaceted approach positions Haut.AI uniquely to support product development cycles from initial research and development through to consumer engagement and market implementation. The firm’s generative AI models and multimodal analytical frameworks aim to revolutionize the understanding of skin aging and enable the creation of adaptive, intelligent applications extending beyond facial skin into realms such as hair analysis and interactive AI interfaces.
Boasting a global clientele that includes industry titans like Ulta Beauty, NAOS, Beiersdorf, and Grupo Boticário, Haut.AI’s technologies have been recognized and trusted across more than 100 organizations worldwide. The company’s commitment to scientific rigor is reflected in its contribution to over 15 peer-reviewed publications and ownership of patented technologies, notably in the area of facial anonymization – a critical consideration for ethical data handling in clinical and commercial skincare research. These innovations support the development of products informed by a nuanced understanding of individual skin characteristics, advancing personalization in dermatological therapies.
.adsslot_c1yIknabOr{ width:728px !important; height:90px !important; }
@media (max-width:1199px) { .adsslot_c1yIknabOr{ width:468px !important; height:60px !important; } }
@media (max-width:767px) { .adsslot_c1yIknabOr{ width:320px !important; height:50px !important; } }
ADVERTISEMENT
At ARDD 2025, Haut.AI will unveil its latest exploratory work within the field of generative AI as it applies to longevity and skin health research. Anastasia Georgievskaya, the company’s CEO and co-founder, is slated to present on August 28 at 16:20. Her talk will delve into the transformative potential of generative artificial intelligence in accelerating discovery and innovation, emphasizing the synergy between advanced computational models and biological insights. This presentation will spotlight the company’s landmark creation, SkinGPT, an award-winning generative AI system that simulates the progression of facial aging and the impact of skincare interventions using sophisticated diffusion modeling techniques.
The SkinGPT platform operates by synthesizing high-fidelity images that mimic age-related changes such as variations in skin texture, pigmentation irregularities, and the emergence of fine wrinkles across demographically diverse cohorts. This technological advancement circumvents the ethical and privacy concerns associated with relying on sensitive real-world datasets by generating synthetic yet biologically plausible imagery for investigation. The approach paves the way for more robust scientific inquiry into visual biomarkers and their correlation with underlying aging mechanisms, offering researchers a powerful tool for hypothesis testing and validation.
Importantly, the ability of generative AI models like SkinGPT to simulate individualized aging trajectories opens new horizons for product innovation in skincare and longevity medicine. Brands and researchers gain unprecedented opportunities to design, test, and personalize interventions based on predictive modeling of the skin’s biological evolution over time. This represents a paradigm shift from traditional skincare development, where empirical testing is often limited by temporal and logistical constraints, to a data-driven, simulation-enabled methodology that can accelerate discovery cycles and optimize clinical efficacy.
The ARDD conference has grown into a critical nexus for knowledge exchange among academia, biotechnology innovators, investors, pharmaceutical leaders, and clinicians. Each year, the meeting features pioneering research and provides a fertile breeding ground for collaboration that spans sectors and disciplines. In 2025, the event will be further distinguished by the presence of Nobel Laureates such as Morten Meldal and Michael Levitt, whose groundbreaking work in molecular design and structural biology has profoundly influenced drug discovery methodologies. Their participation underscores the conference’s commitment to bridging fundamental scientific breakthroughs with translational applications in longevity biotechnology.
University of Copenhagen’s Morten Scheibye-Knudsen, MD, Ph.D., emphasized the instrumental role played by laureates Meldal and Levitt in enabling novel approaches to molecular modeling and rational drug design, which have been integral in accelerating the development of new therapeutic agents. The inclusion of such high-profile scientists highlights ARDD’s stature as a premier platform for advancing cutting-edge research tackling the molecular underpinnings of aging and age-associated diseases.
Daniela Bakula, Ph.D., from the University of Copenhagen, expressed enthusiasm about the augmented scientific program at ARDD2025, citing the confluence of Nobel laureates and industry stalwarts as a catalyst for an unforgettable and impactful conference experience. This sentiment reflects the broader momentum within the longevity research community to harness interdisciplinary innovations and foster collaborations that translate basic science insights into tangible clinical outcomes.
Alex Zhavoronkov, Ph.D., founder and CEO of Insilico Medicine, reflected on ARDD’s evolution over 12 years into the foremost global forum for academia-pharma-startup-investor dialogue in longevity biotechnology. He underscored the unique function of the conference in accelerating partnerships and dialogue that fuel transformative research in aging, emphasizing the inclusion of pharmaceutical executives and healthcare delivery leaders in 2025 as a testimony to the event’s pivotal role in shaping the future of healthy lifespan extension.
Echoing this vision, Prof. Dr. Evelyne Bischof, organizer of the Longevity Medicine Days, highlighted ARDD’s critical emphasis on evidence-based healthy longevity medicine. The presence of Nobel laureates and leading scientists enhances the conference’s mission to reinforce the scientific rigor grounding the emerging field of longevity interventions. The integration of clinical perspectives alongside preclinical and biotechnological insights promises to bridge gaps between discovery and real-world application.
The convergence of aging research with drug discovery has created opportunities for innovative therapeutics with blockbuster potential. Leading pharmaceutical companies such as Novartis, Biogen, and Eli Lilly continue to invest heavily in this domain, reinforcing the vital role ARDD plays as a hub for pioneering research dissemination and industry collaboration. The 2024 conference saw presentations from these companies on their latest projects aimed at extending healthspan, illustrating the rapid progress and growing commercial interest in longevity science.
All stakeholders in the longevity ecosystem are encouraged to participate in ARDD 2025 to contribute to the collective endeavor of redefining healthy aging. The conference facilitates access to trailblazing research, state-of-the-art technologies, and strategic partnerships essential for overcoming the complex biological challenges posed by aging. It stands as a beacon for innovation aiming to transform medicine through longevity biotechnology.
For further inquiries, interviews, or visual materials, interested parties are invited to contact the ARDD media team via [email protected]. Additional details about the conference and Haut.AI’s contributions can be found on their respective web platforms.
Subject of Research: Advances in generative artificial intelligence applied to aging research, skin health, and longevity biotechnology.
Article Title: Haut.AI Sponsors 12th Aging Research & Drug Discovery Meeting: Pioneering Generative AI in Skin and Longevity Science
News Publication Date: Not specified (related to ARDD 2025, announcement date presumed 2024)
Web References:
University of Copenhagen: https://www.ku.dk/english/
Aging Research & Drug Discovery Meeting: https://agingpharma.org/
Haut.AI: http://www.haut.ai/
Keywords: Health and medicine, aging research, drug discovery, generative AI, skin health, personalized skincare, longevity biotechnology, ARDD, artificial intelligence, molecular modeling, aging biomarkers, translational medicine
Tags: aging research biotechnology conferenceAI-driven hair analysis solutionsartificial intelligence in skincareconsumer engagement in skincare technologygenerative AI for skin healthglobal participation in aging conferencesHaut.AI sponsorship at ARDD 2025interdisciplinary approach to aging therapeuticsmarket implementation of AI skincarepersonalized skincare solutionsskin aging research innovationstechnology integration in dermatology